Изучение гипотензивного эффекта правастатина у больных с мягкой артериальной гипертонией и гиперхолестеринемией
Диссертация
Появились данные, свидетельствующие о том, что статины обладают не только гиполипидемическим, но и другими положительными эффектами. Известно, что ингибитор ГМГ-КоА редуктазы правастатин обладает антитромбогенным эффектом, снижает вязкость крови и улучшает эндотелиальную функцию. Это позволяет по-новому взглянуть на статины, в плане их возможности корригировать несколько ФР атеротромбоза… Читать ещё >
Список литературы
- Агеев Ф.Т., Овчинников А. Г., Мареев В. Ю., Беленков Ю. Н. Эндотелиальная дисфункция и сердечная недостаточность:патогенетическая связь и возможности терапии ингибиторами ангиотензинпревращающего фермента. Consilium medicum, 2001 -3(2).
- Аронов Д. М. Средства и методы лечения атеросклероза. Лечение и профилактика атеросклероза, 2000,182−187.
- Аронов Д.М. Плеотропные эффекты статинов. РМЖ, 2001−9(13−14)-578.
- Белоусов Ю.Б., Моисеев B.C., Лепахин В. К. Лекарственные средства при Гиперлипопротеидемии ингибиторы ГМГ-КоА-редуктазы (статины). «Клиническая фармакология и фармакотерапия» Руководство для врачей М., 1997−532с, глава 11.
- Бэр Ф. М. Клиническое значение эндотелиальной дисфункции. Журнал Топ Медицина, 2000 г.,№ 3.
- Дейвид Дж. Майрон, Сергио Фазио, МакРаэ Ф. Линтон. Современные перспективы применения статинов. Международный медицинский журнал, 2000, № 6.
- Джанашия П.Х., Назаренко В. А., Николенко С. А. Дислипопротеидемии: клиника, диагностика, лечение. Учебное пособие, 2000.
- Карпов Ю.А. Лечение стабильной стенокардии:учет метаболических нарушений. РМЖ, 2001- 9(2)-62.
- Лабораторные методы исследования в клинике. Справочник под редакцией В.В. Меньшикова-М.:Мед-на 1987(221−222).
- Лабораторные методы исследования в клинике. Справочник под редакцией В.В. Меньшикова-М.:Мед-на 1987(219−221).
- Лабораторные методы исследования в клинике. Справочник под редакцией В.В. Меньшикова-М.:Мед-на 1987 (225−227).
- Лазебник Л.Б., Комиссаренко И. А., Милюкова О. М. Артериальная гипертония и сопутствующие заболевания. В мире лекарств, 2000- № 3.
- М.Лякишев А. А. Терапия статинами: точка зрения клинического фармаколога. Русский Медицинский Журнал.2001,Том 9, № 1,48−50.
- Ольбинская Л., Мартынов А., Хапаев Б. Мониторирование артериального давления в кардиологии. Москва, 1998 г.
- Сидоренко Б.А., Затейщиков Д. А. Дисфункция эндотелия в патогенезе атеросклероза и его осложнений. Кремлевская медицина. Клинический вестник, 1999−2.
- Сидоренко Б.А., Грацианский Н. А. Современные возможности профилактики атеросклероза. Место правастатина. Клиническая фармакология и терапия, 1996- 5(4), 53−55.
- Смиешко В., Хаютин В. М., Герова М. И др. Чувствительность малой артерии мышечного типа к скорости кровотока: реакция самоприспособления просвета артерии. Физиол. Журн. СССР, 1979−65:2:291−298.
- Сорокин Е.В., Карпов Ю. А. Статины, эндотелий и сердечнососудистый риск. РМЖ 2001, том9(9).
- Шестакова М.В. Дисфункция эндотелия-причина или следствие метаболического синдрома? РМЖ, 2001- 9(2) -88.
- Abetel G, Poget PN, Bonnabry JP. «Hypotensive effect of fluvastatin, an inhibitor of cholesterol synthesis». Novartis Pharma Schweiz AG, Bern,
- Aikawa M, Rabkin E, Sugiyama S, Libby P. An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro. Circulation 2001−103:276−283.
- Alberts AW. Discovery biochemistry and biology of lovastatin. Am. J Cardiol, 1988−62:10J-15J.
- Assman G, Schriewer H, Schmitz G, Hagele E. Quantification of HDL cholesterol by precipitation with phosphotungstic acid/MgCl 2. Clin.Chem.1983, 29- 12, 2025−2029.
- Austin MA. Plasma triglyceride and coronary heart disease. Artcrioscler. Thromb. 1991−11:2−14.
- Azurna H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Brit. J. Pharmacol. 1986- 88: 411−415.
- Bandinelli S, Pucci L, Bertolotto A, Lucchesi D, Navalesi R, Penno G. «Hypotensive effects of HMG-CoA reductase inhibitors: atorvastatin. Journal of Hypertension, 2000-vol. 18(suppl 2), S22-S23.
- Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986,232,34−47.
- Bruning ТА, van Zwiete PA, Blauw GJ, Chang PC. No functional involvement of 5-hydroxytryptainine la receptors in nitric oxide dependent dilation caused by serotonin in the human forearm vascular bed. J. Cardiovascular Pharmacol. 1994- 24: 454−461.
- Bucolo G. Quantitative determination of serum triglycerides by use of enzymes. Clin. Chem. 1973- 19,476−481.
- Byington RP- Davis BR- Plehn JF- White HD- Baker J- Cobbe SM- Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
- Casino PR, Kilcoyne CM, Quyumi AA, Hoeg JM, Panza JA. The role at nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients, Circulation, 1993, 88: 2541−2547.
- Castelli WP, Wilson WP, Levy D, et al. Cardiovascular risk factors in the elderly. Am.J.Cardiol. 1989−63:12−19.
- Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994- 14: 753−759.
- Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992- 340:1111−1115.
- Comwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Amer. J. Physiol. 1994- 267: С1405−1413.
- Cooke J. P, Tsao P. S. Is NO an endogenous antiathero-genic molecule? Arterioscler. Thromb. 1994- 14: 653−655.
- Coronary Heart Disease: Reducing the Risk. The scientific backgroud for primary and secondary prevention of coronary heart disease. Nutrition, Metebolism and Cardiovascular Diseases. 1998- vol.8, № 4, 212−247.
- Corsini A., Bernini F., Quarato P., Donetti E., Bellosta S., Fumagalli R., Paoletti R., Soma V.M. Non-lipid-related effects of 3-hydroxy-methylglutaril coenzyme A reductase inhibitors. Cardiology 1996- 87: 458−468.
- Dangas G, Badimon JJ,.Smith DA et al. Pravastatin Therapy in Hyperlipidemia: Effects on Thrombus Formation and the Systemic Hemostatic Profile. J American College of Cardiology 1999−33:1294−1304.
- Davies M.J., Thomas A.C. Plaque Assuring the cause of acute myocardial infarction, sudden ischemic death, and creshendo angina. Brit. Heart Journ., 1985: 53: 363−373.
- Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and look a head. Can. J. Cardiol., 1992,8,843−864.
- De Graaf JC, Banga JD, Moncada S et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 1992- 85: 22 842 290.
- Devereux RB, Lutas EM, Casale PN, et al. Standartisation of M-node echocardiographic determined left ventricular anatomic measurement. J.Am.Coll. Cardiol., 1984,4: 1222−1230.
- Devereux RV, Koren MJ, De Simone G, et al. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur. Heart J., 1993- 14: D8−15.
- Dobrucki LW, Kalinovski L, Malinski T. Statin-stimulated nitric oxide release from endothelium. Med Sci Monit. 2001 Jul-Aug-7(4):622−7.
- Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998−279:164 5-J 622.
- Egashira K, HirookaY, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation, 1994- Vol.89, № 6,2519−2524.
- Endo A, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot 1976- 29:13 461 348.
- Esther CRJr, Marino EM, Howard ТЕ et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest. 1997:99: 2375−2385.
- Falk E., Shah PK, Faster V. Coronary plaque disruption. Circulation, 1995−92:657−671.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin.Chem., 1972- 18:499.
- Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertropliy? Amer. J. Cardiol. 1979: 44: 959−963.
- Frohlich ED. Overview of hemoilynamic factors associated with left ventricular hypertrophy. J. Mol. Cell. Cardiol., 1989: 21:3−10.
- Furberg CD, Pitt B, Byington R, Park J-S, McGovern ME for the PLAC I and PLAC II Investigators. Reduction in coronary events during treatment with pravastatin. Am.J.Cardiol., 1995, 76, 60C-63C.
- Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature 1980- 288: 373 376.
- Fuster V., Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation, 1994: 90: 2126−2146.
- GloriosoN, Troffa C, Filigheddu F, Dettori F, Soro A, et al. «Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia». Hypertension, 1999- 34:12 811 286.
- Goldstein LB., Adams R, Becker К et al. AHA Scientific Statement: Primary Prevention of Ischemic Stroke. A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association. Stroke 2001,32:280.
- Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994- 74: 1141−1148.
- Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997- 96: 3264−3265.
- Hahn A.W., Resink T.J., Scott-Burden T. et al. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regulation. 1990- 1: 649−659.
- Hamson ЕЮ. Endothelial function and oxidant stress. Clin. Cardiol. 1997- 20 (SII): II-11-II-17.
- Heitzer Т., Via Herttuala S., Luoma J. et al. Cigarette smoking potentiates endothelial dislunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 1996,93: 1346−1353.
- Hsu I, Spinier SA, Johnson N. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother., 1995,29,743−759.
- Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. AmJCardiol. 1998Dec 1 -82(1 1): 13 57−63.
- Circulation 2001 Jan 23−103(3):387−92.
- Keidar S, Aviram M, Maor I et al. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin Pharmac 1994−39:513−519.
- Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collgen synthesis in cultured vascular smooth cells. Circul. Res. 1995- 76: 305−309.
- Rubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA., 1991- 88: 46 514 655.
- Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Amer. J. Physiol. 1992- 262: H611-H615.
- Lacoste L., J.v. Lam, J. Hung et al. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potencial with cholesterol reduction. Circulation, 1995:92, II, 3172−3177.
- Lasher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Basic Research. Cardiol. 1993- 88(SI): 15−24.
- Laufs U, La Fata V, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorse. Circulation, 1998- 97,11 251 135.
- Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994−308:367−373.
- Lefer AM. Nitric oxide: Nature’s naturally occuring leukocyte inhibitor. Circulation, 1997- 95: 553−554.
- Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts forcardiovascular disease. Cardiovascular Research. J of European Society of Cardiology 2001- Vol 49, 2:281−287.
- Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atlierosclerotic coronary arteries. New Engl. J. Mod. 1986, 315: 1046−1051.
- Lusher Т., Vanhoutte P. The Endothelium: Modulator Of Cardiovascular Function. Boca Raton, Fla- CRC Press.- 1990: 1−228.
- Lusher T.F., Barton M. Biology of the endothelium. Clin. Cardiol, 1997- 10 (suppl 11), II-3-II-10.
- Mac Mahon S.W. // Aterosclerosis 1985. — Vol.5 — pp.391−396.
- Marcheli S, Lupatteli G, Siepi D, Schillaci G, Sinzinger H, Mannarino E., et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J cardiovasc Pharmacol. 2000 Nov-36(5):617−21.
- McNamara DB, Bedi B, Aurora H et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem. Biophys. Res. Commun. 1993- 1993:291−296.
- Mullen MJ, Clarkson P, Thorne SA, Donald AE, Thompson H, Powe AJ, Deanfield JE. «Effects of cholesterol lowering on brachial artery endothelial function in young subjects with moderate hypercholesterolemia». Circulation, 1997,96,8,suppl. 1,672.
- Nakashima Y, Toyokawa T, Tanaka S, Yamashita K, Yashiro A, Tasaki A, Kuroiwa A «Simvastatin increases plasma N02-and NOa- levels in patients with hypercholesterolemia». Atherosclerosis, 1996- 127,43−47.
- Palmer, R. M. J., Ferrige, A. G., and Moncada, S. (1987) Nature, 327, 524−526.
- Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Europ.J.Clin. Pharmacol.-40,Suppl.-S15−18.
- Pan HY, De Vault AR. Pharmacokinetics and pharmadynamics of pravastatin. J.Clin.Pharmacol.Ther.-48:2−1990−201−207.
- Plehn JF, Davis BR, Sacks FM et al. Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999−99:216−223
- Prevention of Coronary Heart Disease in Clinical Practice. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Eur Heart J 1998- 19: 1434−1503.
- Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995−346:1647−1653.
- Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMO-dependent protein phosphorviation Nature, 1983:306: 174−176.
- Recommendations of the German Society for clinical chemistry. Z.Klin.Chem.Klin.Biochem, 1972- V. 10p.281 -286.
- Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998−98:839−44.
- Ridker PM, Gaboury CL, Conlin PR et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993- 87: 1969−1973.
- Rimm E.B., Stampfer M.J., Ciovannucci E. et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995−141: 1117—1127.
- Robert L. Judd, PhD. Future Trends in the Pharmacologic Treatment of Hypertension. Auburn University, Graduate Program in Biomedical Sciences, Department of Anatomy, Physiology and Pharmacology, 2001.
- Roeschlau P, Bendt E, Gruber W. Enzimatishe bestimmung des gesamt scholestekines in serum. Zz.Klin.Chem.Clin.Biochem., 1974- 12,226−229.
- Rosensen RS, Tangney CC, Casey LC. Inhibition of pro-inflammatory cytokine production by pravastatin. Lancet 1999−353:983−984.
- Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998−279:1643−1650.
- Rumley A., G.D.O. Lowe, J. Norrie, I. Ford, J. Shepherd, S.M. Cobbe: Blood rheology and outcome in the West of Scotland Coronary Prevention Study. Br.J.Haematol. 97,78- 1997. Abstract.
- Rauch U, Osende JI, Chesebro JH, Fuster V, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ., et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000 ov- 153(1): 181 -9.
- Reichek N, Devereux RV. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation, 1981−63:1391−1398.
- Sarkar R., Meinberg EG, Stanley JC et al. Nitric oxide reversibility inhibits the migration of cultured vascular smooth muscle cells. Circ. Res. 1996: 78: 225−230.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344: 1383 1389.
- Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med 2001- 7:189−191.
- Schachinger V, Britten MB, Zeiher AM «Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease» Circulation, 2000- 101:1899−1906.
- Shechter M, Sharir M, Labrador MJ, Forrester J, Merz CN. Improvement in endothelium-dependent brachial artery flow-mediatedvasodilation with low-density lipoprotein cholesterol levels <100 mg/dl.Am J Cardiol. 2000 Dec 1−86(11): 1256−9, A6.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New. Engl. J. Med, 1995,333,20,1301 -1307.
- Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta.Atherosclerosis. 2001 Mar-155(l):245−50.
- Schmieder R. E, John S, Langenfeld M, et al. J.Am. Coll.Cardiol., 1997-(suppl-A), 85A.
- Sinoway L.I., Hendrickson C., Davidson W.R., et al. Caracteristics of flow mediated brachial artery vasodilatation in human subjets//Circ Res 1989- 64: 32−42.
- Stroes ES, Koomans HA, de Bmin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet, 1995- 346: 467−471.
- Stamler JS. Redox signaling: nitrosylation and related target interactions onnitricoxide. Cell, 1994−74:931 -938.
- Tarry WC, Makhoul RG. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler. Thromb. 1994: 14:938−943.
- Teichholz LE, Kreulen T, Herman MV. Problems in echocardiographic volume determination echocardiographic-angiographic correlation in the presentic or absense of asynergy. Am.J.Cardiol., 1976−37:7−11.
- The Prospective Cardiovascular Munster Study: prevalence and prognostic significance of hypelipidemia in men with systemic hypertension. Am. J.Cardiol., 1987−59:9G-17G.
- Treasure C.B., Klein J.L., Weintraub W.S., et al. N.Engl.J.Med., 1995- Vol.332, № 8, 481−487.
- Treasure CB, Manoukian SV, Klem JL. et al. Epicardial coronary artery response to acetylcholine are impared in hypertensive patients. Circ. Research 1992−71:776−781.
- Tsao PS, Wang B, Buitrago R., Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation. 1997- 97: 934−940.
- Vane J.R., Anggard E.E., Batting R.M. Regulatory functions of the vascular endotnelium. New England Journal of Medicine, 1990: 323: 27−36.
- Van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, Lancelma J, Emeis jJ, van Hinsbergh VW «Simvastatin improves disturbed endothelial barrier function» Circulation, 2000−102(23):2803−2809.
- Vanhoutte P.M. How to assess endothelial function in human blood vessels//J Hypertens 1999- 17: 1947−058.
- Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expresiion of plasminogen activator inhibitor-1 in cultured endothelial cells. J. Clin. Invest. 1995- 95: 995−1001.
- Vaughan DE. Endothelial function, fibrinolysis, and angiotensyn-converting enzym inhibition. Clin. Cardiology. 1997- 20 (SII): II-34-II-37.
- West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 1998,97, 1440−1445
- White H D, Simes R. J, Anderson NE et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000−343:317−26.
- Wilson PWF, William P, et al. Coronary risk prediction in adults (The Framingham Heart study). Am.J.Cardiol.1987- 59:91G-94G.
- Zeiher AM, Schachinger V., Minnenf. Long-term cigarette smoking impairs endotheliu in-dependent coronary arterial vasodilator function. Circulation, 1995: 92: 1094−1100.
- Zeiker AM, Fisslthaler B, Schray Utz B, Basse R. Nitric oxide modulates the expression of monocyte chemoat-tractant protein I in cultured human endothelial cells. Circ. Res. 1995- 76: 980−986.